NASDAQ:MORF - Nasdaq - US61775R1059 - Common Stock - Currency: USD
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic...
Mentions: LLY
Eli Lilly & Co. is selling US investment-grade bonds on Monday to fund its $3.2 billion acquisition of gut-drug maker Morphic Holding Inc., after recession fears triggered a turbulent week.
Mentions: LLY
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Morphic Holding (NASDAQ:MORF) just reported results for the second quarter of 2...
MORF stock results show that Morphic Holding missed analyst estimates for earnings per share the second quarter of 2024.
Mentions: SHCR
How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand.
Investing in generational wealth stocks means holding them for years, preferably decades, to allow them to deliver supercharged returns.
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: PRMW
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts.
Mentions: SPR
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to strengthen Eli Lilly's pipeline, complementing existing assets.
Give some consideration to these names, each of which has a strong competitive advantage and catalysts driving their share price higher.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: DM
Patients lost more more weight on Mounjaro than Ozempic.
Microsoft layoffs hit the tech giant's employees last week as it reduced an unknown number of roles in two of its divisions.